Drug intelligence / Profile preview

ABBV-711

Development stage: Phase 1
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

ABBV-711 is an investigational, orally administered small-molecule anticancer drug being developed by AbbVie for the treatment of advanced solid tumors, with an initial focus on squamous non-small cell lung cancer and head and neck squamous cell carcinoma.[4][7][13] Although its precise molecular target and mechanism of action have not been publicly disclosed, ABBV-711 is being evaluated as a monotherapy and in combination with the anti–PD-1 monoclonal antibody budigalimab (ABBV-181) in early-phase clinical trials, reflecting a strategy to enhance antitumor immunity in squamous malignancies.[4][14]

Targets

PRMT5 (Protein arginine N-methyltransferase 5)

Beyond the preview

Go deeper on ABBV-711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-711.

Explore the full profile